IPO - Coeptis Therapeutics Holdings, Inc.

Form Type: 424B4

Filing Date: 2025-04-23

Corporate Action: Ipo

Type: New

Accession Number: 000168316825002761

Filing Summary: Coeptis Therapeutics Holdings, Inc. is offering up to 3,919,349 shares of its common stock by named Selling Stockholders. The Offering involves: (i) 100,000 shares that the Company can issue or sell to Selling Stockholders; (ii) up to 3,737,472 shares issued or to be issued to YA II PN, LTD. according to a Standby Equity Purchase Agreement (SEPA) dated November 1, 2024; and (iii) 81,877 shares related to the partial conversion of a convertible note. Although the Company will not receive proceeds from the Selling Stockholders’ sales, it may garner up to $20 million from sales to Yorkville under the SEPA. The document also outlines operational strategies post-reverse stock split completed on December 30, 2024, and mentions the Company’s transition from a SPAC to a biopharmaceutical entity that aims to develop cell therapy platforms targeting critical therapeutic areas. The company acquired Coeptis Therapeutics, Inc. through a reverse merger and now operates alongside its subsidiaries. Future offerings may be made depending on market conditions. As of April 21, 2025, COEP's stock price was reported at $10.77 per share, displaying the company's public offering in progress which aligns with regulatory guidelines for an emerging growth company.

Form Type: S-1/A

Filing Date: 2025-04-04

Corporate Action: Ipo

Type: Update

Accession Number: 000168316825002278

Filing Summary: Coeptis Therapeutics Holdings, Inc. filed an updated registration statement on Form S-1/A for the resale of up to 3,919,349 shares of common stock by selling stockholders, which includes shares to be sold under a Standby Equity Purchase Agreement (SEPA) with Yorkville. The registration relates to both newly issued shares and shares purchased in conjunction with a conversion of an outstanding convertible note. The SEPA arrangement includes a commitment for the sale of shares that may aggregate $20 million in proceeds. This document notes that the common stock is subject to a recent reverse split executed on December 30, 2024, with current trading on the Nasdaq Capital Market under the symbol COEP. The prospectus also emphasizes the high investment risks associated with securities and is structured to comply with the reduced reporting requirements for emerging growth companies.

Form Type: S-1/A

Filing Date: 2025-02-07

Corporate Action: Ipo

Type: Update

Accession Number: 000168316825000839

Filing Summary: On February 7, 2025, Coeptis Therapeutics Holdings, Inc. filed Form S-1/A, a preliminary prospectus for the resale of up to 3,919,349 shares of common stock by designated selling stockholders. The offering includes 100,000 shares directly held by these stockholders and 3,737,472 shares involved in an agreement with YA II PN, LTD under a Standby Equity Purchase Agreement (SEPA). The prospectus indicates that the company will not receive proceeds from shareholders' sales but may receive up to $20 million through potential sales of common stock to Yorkville. This filing follows a recent 1-for-20 reverse stock split effective December 30, 2024, and the current listed price of the stock is $10.78 per share. The document also outlines the risks related to investing and the evolving status of the company as an emerging growth entity under the SEC regulations.

Form Type: S-1

Filing Date: 2025-01-10

Corporate Action: Ipo

Type: New

Accession Number: 000168316825000229

Filing Summary: Coeptis Therapeutics Holdings, Inc. filed an S-1 registration statement with the SEC for the resale of up to 3,919,349 shares of common stock by selling stockholders. This includes 100,000 shares directly held by the selling stockholders, 3,737,472 shares that may be issued to a specific selling stockholder, YA II PN, LTD., under a Standby Equity Purchase Agreement (SEPA), and 81,877 shares linked to the conversion of an outstanding convertible note. The filing indicates that the company will not receive any proceeds from these sales, though it could receive up to $20 million from sales made under the SEPA. The document highlights that the common stock is subject to a 1-for-20 reverse stock split effective December 30, 2024, and gives an estimated last reported sale price of $5.91 per share as of January 8, 2025. The company is classified as an emerging growth company, allowing it to provide a reduced level of public reporting, and states that investing in its securities involves a high degree of risk.